Product News

First MelMax shipment sent to Europe

November 18, 2005

Rob Rueger, Greystone's Director of Manufacturing, completed and shipped the first batch of MelMax for subsequent sales and distribution by Dermagenics BV – Greystone's wholly owned European subsidiary.

MelMax cleared for sale in Europe

October 10, 2005

MelMax, Greystone's bacteriostatic wound dressing, has been cleared for sale in Europe as a class IIb medical device similar to DerMax. MelMax contains one-fourth the quantity of PHI used in DerMax, but also contains a bacteriostatic honey-based ointment. Honey-based wound dressings are becoming popular in Europe for treating infected wounds or wounds that are prone to becoming infected.

FDA clears Epi-Max for sale and use in U.S.

May 18, 2005

Epi-Max was cleared by the U.S. Food and Drug Administration for human use and sale in the United States. Epi-Max is a hybrid medical device with a drug component, which makes it significantly different from most other advanced wound care products. Click here for the full press release.